TARDBP and Lewy body dementia: Due to the ubiquitous nature of TDP-43 expression, it may not be a viable therapeutic approach to target TDP-43 in a generalized manner; however, strategies to modify the TDP-43 toxicity and to reduce TDP-43 aggregation may not only benefit FTLD and ALS patients [175], but also be relevant to more common age-related neurodegenerative disorders such as AD, Lewy body dementia, and LATE.